A Study of YL-17231 in Patients With Advanced Solid Tumors
收藏NIAID Data Ecosystem2026-05-01 收录
官方服务：
资源简介：
This is a phase 1 open label multicenter study to evaluate the maximum tolerance, safety, tolerance and PK of oral YL-17231 in patients with advanced solid tumors with KRAS mutation, so as to confirm the recommended phase 2 dose of YL-17231 and obtain the preliminary efficacy information of patients with advanced solid tumors with KRAS mutation.
创建时间：
2023-09-15
